Psoriasis treatments, particularly systemic therapies like methotrexate, cyclosporin, and TNF inhibitors, carry varying levels of cancer risk, predominantly for non-melanoma skin cancers and lymphoproliferative disorders. The gene discussed is TNF; the disease is lymphoproliferative syndrome.